Reported Friday, NeuroSense Therapeutics Receives Dual Nasdaq Non-Compliance Notices For Minimum Bid Price And $35M Market Value Requirements, Given Until September 29, 2026

Benzinga Newsdesk www.benzinga.com Positive 90.5%

Neg 0% Neu 0% Pos 90.5%

Notifications have no immediate effect on the listing or trading of the Company's securities on Nasdaq
Nasdaq has provided the Company until September 29, 2026 to regain compliance with both requirements
The Company is actively evaluating actions to regain compliance, with a clear focus on initiatives that are aligned with and supportive of long-term shareholder value

Comments

No comments yet. Be the first!